Between 2011 and 2015, Datamonitor Healthcare's Big Pharma and Mid Pharma peer sets, which include 27 companies (located outside of Japan) that have annual prescription sales of greater than $1 billion, signed 229 immuno-oncology deals, with transaction volume rising at a compound annual growth rate of 65%.
The dataset includes traditional licensing agreements where rights for a certain drug are exchanged, and also collaborative combination agreements in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?